Susquehanna International Group
ALXN

Susquehanna International Group’s Alexion Pharmaceuticals ALXN Stock Holding History

Susquehanna International Group’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-232,700
Closed -$42.7M – 14112
2021
Q2 		$42.7M Sell
232,700
-37,700
-14% -$6.47M 0.01% 1312
2021
Q1 		$41.3M Sell
270,400
-396,500
-59% -$61.3M 0.01% 1249
2020
Q4 		$104M Sell
666,900
-27,400
-4% -$3.52M 0.02% 643
2020
Q3 		$79.4M Sell
694,300
-250,200
-26% -$27M 0.02% 656
2020
Q2 		$106M Sell
944,500
-326,100
-26% -$34.6M 0.03% 482
2020
Q1 		$114M Sell
1,270,600
-41,300
-3% -$4.05M 0.04% 346
2019
Q4 		$142M Buy
1,311,900
+439,000
+50% +$47M 0.04% 366
2019
Q3 		$85.5M Buy
872,900
+419,800
+93% +$47.3M 0.03% 505
2019
Q2 		$59.3M Buy
453,100
+27,400
+6% +$3.53M 0.02% 604
2019
Q1 		$57.5M Sell
425,700
-159,600
-27% -$19.8M 0.02% 556
2018
Q4 		$57M Sell
585,300
-57,400
-9% -$6.78M 0.02% 556
2018
Q3 		$89.3M Sell
642,700
-500,400
-44% -$62.8M 0.03% 477
2018
Q2 		$142M Sell
1,143,100
-185,300
-14% -$21.7M 0.05% 314
2018
Q1 		$148M Buy
1,328,400
+616,000
+86% +$73.6M 0.05% 279
2017
Q4 		$85.2M Sell
712,400
-65,600
-8% -$7.99M 0.03% 473
2017
Q3 		$109M Sell
778,000
-314,600
-29% -$42.7M 0.04% 355
2017
Q2 		$133M Buy
1,092,600
+547,900
+101% +$63.8M 0.06% 274
2017
Q1 		$66M Sell
544,700
-481,000
-47% -$62M 0.03% 460
2016
Q4 		$125M Buy
1,025,700
+567,300
+124% +$69.4M 0.06% 263
2016
Q3 		$56.2M Sell
458,400
-66,400
-13% -$8.55M 0.03% 505
2016
Q2 		$61.3M Buy
524,800
+228,800
+77% +$32.5M 0.03% 444
2016
Q1 		$41.2M Buy
296,000
+39,900
+16% +$5.86M 0.02% 603
2015
Q4 		$48.9M Sell
256,100
-412,700
-62% -$72.1M 0.02% 615
2015
Q3 		$105M Sell
668,800
-475,200
-42% -$86.7M 0.05% 365
2015
Q2 		$207M Buy
1,144,000
+938,500
+457% +$162M 0.09% 190
2015
Q1 		$35.6M Sell
205,500
-129,100
-39% -$23.4M 0.02% 826
2014
Q4 		$61.9M Sell
334,600
-73,600
-18% -$13.6M 0.02% 618
2014
Q3 		$67.7M Sell
408,200
-3,100
-0.8% -$509K 0.03% 580
2014
Q2 		$64.3M Buy
411,300
+69,100
+20% +$10.9M 0.03% 571
2014
Q1 		$52.1M Buy
342,200
+87,800
+35% +$14M 0.02% 609
2013
Q4 		$33.9M Sell
254,400
-79,500
-24% -$9.54M 0.02% 901
2013
Q3 		$38.8M Buy
333,900
+69,400
+26% +$7.61M 0.02% 739
2013
Q2 		$24.4M Buy
+264,500
New +$25.5M 0.01% 970

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Susquehanna International Group's ALXN Position: Q3 2021 in Review

Susquehanna International Group sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 81,039 shares — an estimated $14.9M sold.

Susquehanna International Group first reported a position in ALXN in Q2 2013 and held it in 32 quarters. The position peaked at $78.8M in Q1 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Susquehanna International Group reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Susquehanna International Group sold 81,039 Alexion Pharmaceuticals shares in Q3 2021, an estimated $14.9M.
  • Susquehanna International Group first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 32 quarters.
  • Susquehanna International Group's Alexion Pharmaceuticals position peaked at $78.8M in Q1 2020.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Susquehanna International Group's 13F filing for Q3 2021, filed 15 Nov 2021.